tradingkey.logo

10X Genomics Inc

TXG
20.460USD
+1.170+6.07%
收盘 01/09, 16:00美东报价延迟15分钟
2.59B总市值
亏损市盈率 TTM

10X Genomics Inc

20.460
+1.170+6.07%

关于 10X Genomics Inc 公司

10x Genomics, Inc. is a life science technology company. The Company's integrated solutions include instruments, consumables and software for single cell and spatial biology systems. Its single cell portfolio, powered by Chromium platform, includes its Chromium X Series, Chromium Connect and legacy Chromium Controller instruments, microfluidic chips and related consumables, which enables throughput analysis of individual biological components. Its Visium platform enables researchers to understand the spatial positions of biological analytes within tissues at high resolution. Its Xenium platform for in situ analysis is designed to give scientists the ability to not only locate and type cells in their tissue context. Its products include Chromium Single Cell Gene Expression, Chromium Single Cell Gene Expression Flex, Chromium Single Cell Immune Profiling, Chromium Single Cell assay for transposase accessible chromatin (ATAC), Visium Spatial Gene Expression, and others.

10X Genomics Inc简介

公司代码TXG
公司名称10X Genomics Inc
上市日期Sep 12, 2019
CEOSaxonov (Serge Wilson)
员工数量1306
证券类型Ordinary Share
年结日Sep 12
公司地址6230 Stoneridge Mall Road
城市PLEASANTON
上市交易所NASDAQ OMX - NASDAQ BASIC
国家United States of America
邮编94588
电话19254017300
网址https://www.10xgenomics.com/
公司代码TXG
上市日期Sep 12, 2019
CEOSaxonov (Serge Wilson)

10X Genomics Inc公司高管

名称
名称/职务
职务
持股
持股变动
Mr. Serge Wilson Saxonov, Ph.D.
Mr. Serge Wilson Saxonov, Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
1.04M
-13261.00%
Dr. John R. Stuelpnagel
Dr. John R. Stuelpnagel
Independent Chairman of the Board
Independent Chairman of the Board
369.61K
+15357.00%
Whitaker (Eric S)
Whitaker (Eric S)
Chief Legal Officer
Chief Legal Officer
202.20K
+45563.00%
Mr. Sridhar (Sri) Kosaraju
Mr. Sridhar (Sri) Kosaraju
Independent Director
Independent Director
59.45K
+15357.00%
Dr. Benjamin J. Hindson, Ph.D.
Dr. Benjamin J. Hindson, Ph.D.
President, Co-Founder, Chief Scientific Officer, Director
President, Co-Founder, Chief Scientific Officer, Director
36.41K
-8283.00%
Ms. Kimberly J. (Kim) Popovits
Ms. Kimberly J. (Kim) Popovits
Independent Director
Independent Director
28.62K
+15357.00%
Dr. Shehnaaz Suliman, M.D.
Dr. Shehnaaz Suliman, M.D.
Independent Director
Independent Director
28.62K
+15357.00%
Mr. Alan V. Mateo
Mr. Alan V. Mateo
Independent Director
Independent Director
--
--
Dr. Sarah A. Teichmann
Dr. Sarah A. Teichmann
Independent Director
Independent Director
--
--
Mr. Adam S. Taich
Mr. Adam S. Taich
Chief Financial Officer
Chief Financial Officer
--
--
名称
名称/职务
职务
持股
持股变动
Mr. Serge Wilson Saxonov, Ph.D.
Mr. Serge Wilson Saxonov, Ph.D.
Chief Executive Officer, Co-Founder, Director
Chief Executive Officer, Co-Founder, Director
1.04M
-13261.00%
Dr. John R. Stuelpnagel
Dr. John R. Stuelpnagel
Independent Chairman of the Board
Independent Chairman of the Board
369.61K
+15357.00%
Whitaker (Eric S)
Whitaker (Eric S)
Chief Legal Officer
Chief Legal Officer
202.20K
+45563.00%
Mr. Sridhar (Sri) Kosaraju
Mr. Sridhar (Sri) Kosaraju
Independent Director
Independent Director
59.45K
+15357.00%
Dr. Benjamin J. Hindson, Ph.D.
Dr. Benjamin J. Hindson, Ph.D.
President, Co-Founder, Chief Scientific Officer, Director
President, Co-Founder, Chief Scientific Officer, Director
36.41K
-8283.00%
Ms. Kimberly J. (Kim) Popovits
Ms. Kimberly J. (Kim) Popovits
Independent Director
Independent Director
28.62K
+15357.00%

收入明细

单位: USD更新时间: 1月6日 周二
单位: USD更新时间: 1月6日 周二
FY2025Q3
FY2025Q2
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2021
FY2020
FY2019
业务USD
名称
营收
占比
Consumables
127.89M
85.83%
Instruments
12.00M
8.05%
Services
8.13M
5.45%
License and royalty revenue
983.00K
0.66%
地区USD
名称
营收
占比
United States
77.25M
51.84%
Europe, the Middle East and Africa
41.62M
27.94%
China
15.19M
10.19%
Asia Pacific
12.32M
8.27%
Americas
2.63M
1.76%
业务
地区
业务USD
名称
营收
占比
Consumables
127.89M
85.83%
Instruments
12.00M
8.05%
Services
8.13M
5.45%
License and royalty revenue
983.00K
0.66%

股东统计

更新时间: 11月19日 周三
更新时间: 11月19日 周三
持股股东
股东类型
持股股东
持股股东
占比
The Vanguard Group, Inc.
11.38%
ARK Investment Management LLC
10.21%
BlackRock Institutional Trust Company, N.A.
6.68%
Fidelity Management & Research Company LLC
6.19%
Millennium Management LLC
4.67%
其他
60.88%
持股股东
持股股东
占比
The Vanguard Group, Inc.
11.38%
ARK Investment Management LLC
10.21%
BlackRock Institutional Trust Company, N.A.
6.68%
Fidelity Management & Research Company LLC
6.19%
Millennium Management LLC
4.67%
其他
60.88%
股东类型
持股股东
占比
Investment Advisor
52.34%
Investment Advisor/Hedge Fund
27.24%
Hedge Fund
14.51%
Research Firm
6.24%
Bank and Trust
5.01%
Venture Capital
1.88%
Individual Investor
1.80%
Family Office
0.84%
Pension Fund
0.54%

机构持股

更新时间: 1月1日 周四
更新时间: 1月1日 周四
报告期
机构数
持股数
持股占比
持股变动
2025Q4
684
126.11M
108.27%
-15.61M
2025Q3
675
117.21M
102.45%
-24.61M
2025Q2
669
120.42M
108.39%
-15.20M
2025Q1
687
115.67M
104.27%
-8.84M
2024Q4
689
107.08M
98.92%
-12.41M
2024Q3
682
106.90M
100.39%
-9.08M
2024Q2
691
105.36M
99.70%
-5.09M
2024Q1
762
106.36M
101.17%
-3.12M
2023Q4
817
100.80M
96.01%
-9.73M
2023Q3
835
96.86M
93.80%
-12.55M
查看更多

股东持股明细

名称
持股数
占比
持股变动
变动比例
公告日期
The Vanguard Group, Inc.
13.25M
11.38%
+834.27K
+6.72%
Sep 30, 2025
ARK Investment Management LLC
11.89M
10.21%
-2.00M
-14.43%
Sep 30, 2025
BlackRock Institutional Trust Company, N.A.
7.78M
6.68%
+194.98K
+2.57%
Sep 30, 2025
Fidelity Management & Research Company LLC
7.21M
6.19%
-430.91K
-5.64%
Sep 30, 2025
Millennium Management LLC
5.44M
4.67%
+2.55M
+88.57%
Sep 30, 2025
Sumitomo Mitsui Trust Bank, Limited
5.38M
4.62%
-636.74K
-10.58%
Sep 30, 2025
Amova Asset Management Co., Ltd.
5.38M
4.62%
+5.38M
--
Sep 30, 2025
Wellington Management Company, LLP
4.29M
3.68%
+2.39M
+126.60%
Sep 30, 2025
Quantinno Capital Management LP
3.49M
3%
+1.26M
+56.37%
Sep 30, 2025
BofA Global Research (US)
3.30M
2.83%
+393.85K
+13.55%
Sep 30, 2025
查看更多

持股ETF

更新时间: 12月2日 周二
更新时间: 12月2日 周二
机构名称
占比
ARK Genomic Revolution ETF
4.02%
Simplify Health Care ETF
2.89%
Janus Henderson Small Cap Growth Alpha ETF
1.66%
Global X Genomics & Biotechnology ETF
1.56%
ARK Innovation ETF
1.3%
WisdomTree BioRevolution Fund
1.28%
Janus Henderson Small/Mid Cap Growth Alpha ETF
1.17%
Harbor Long-Short Equity ETF
0.61%
First Trust Nasdaq Lux Digi Health Solutions ETF
0.53%
Invesco NASDAQ Future Gen 200 ETF
0.52%
查看更多
ARK Genomic Revolution ETF
占比4.02%
Simplify Health Care ETF
占比2.89%
Janus Henderson Small Cap Growth Alpha ETF
占比1.66%
Global X Genomics & Biotechnology ETF
占比1.56%
ARK Innovation ETF
占比1.3%
WisdomTree BioRevolution Fund
占比1.28%
Janus Henderson Small/Mid Cap Growth Alpha ETF
占比1.17%
Harbor Long-Short Equity ETF
占比0.61%
First Trust Nasdaq Lux Digi Health Solutions ETF
占比0.53%
Invesco NASDAQ Future Gen 200 ETF
占比0.52%

分红派息

近5年累计派现 0.00 美元
公告日期
分红计划
股权登记日
现金发放日
除权除息日
暂无数据

拆合股

公告日期
类型
比率
暂无数据
公告日期
类型
比率
暂无数据

常见问题

10X Genomics Inc的前五大股东是谁?

10X Genomics Inc 的前五大股东如下:
The Vanguard Group, Inc.持有股份:13.25M,占总股份比例:11.38%。
ARK Investment Management LLC持有股份:11.89M,占总股份比例:10.21%。
BlackRock Institutional Trust Company, N.A.持有股份:7.78M,占总股份比例:6.68%。
Fidelity Management & Research Company LLC持有股份:7.21M,占总股份比例:6.19%。
Millennium Management LLC持有股份:5.44M,占总股份比例:4.67%。

10X Genomics Inc的前三大股东类型是什么?

10X Genomics Inc 的前三大股东类型分别是:
The Vanguard Group, Inc.
ARK Investment Management LLC
BlackRock Institutional Trust Company, N.A.

有多少机构持有10X Genomics Inc(TXG)的股份?

截至2025Q4,共有684家机构持有10X Genomics Inc的股份,合计持有的股份价值约为126.11M,占公司总股份的108.27%。与2025Q3相比,机构持股有所增加,增幅为5.82%。

哪个业务部门对10X Genomics Inc的收入贡献最大?

在FY2025Q3,Consumables业务部门对10X Genomics Inc的收入贡献最大,创收127.89M,占总收入的85.83%。
KeyAI